drugset / Trial / NCT04352361

Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy Subjects

NCT04352361

Phase 1 Completed 34 enrolled Ascletis Pharmaceuticals Co., Ltd.
RandomizedParallel-groupSingle-blindTreatment

Summary

Ascending oral single-dose study to evaluate the safety and pharmacokinetics of TVB- 2640 tablets in the Chinese healthy population.

Timeline

Start
2020-04-02
Primary completion
2020-04-29
Completion
2020-04-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Denifanstat Small molecule 25 mg Oral
Subject Denifanstat Small molecule 50 mg Oral
Subject Denifanstat Small molecule 75 mg Oral

Indications

No indication recorded.